Inbios International, Inc.

James William Needham

Syamal Raychaudhuri

Stanislaw Morkowski

Raymond L Houghton

Yvonne Stevens

Mohua Bose

Hongjing Chen

Mazbahul Kabir

Gregory Ireton

Dindo Reyes

Gustavo Firnhaber

Koji Abe

Embodiments are directed to use of a rapid-test-validation computing device to determine if a result of a rapid test device is valid and identify the result. The rapid-test-validation computing device captures images of the rapid test device and employs a first artificial intelligence mechanism to determine if the rapid test device is properly aligned in the images. The rapid-test-validation computing device then employs a second artificial intelligence mechanism to determine if a result of the rapid test device is valid or invalid. If the result is valid, the rapid-test-validation computing device employs a third artificial intelligence mechanism to determine and present an objective output of the rapid test device result to a user; otherwise, the rapid-test-validation computing device presents a notification to the user that the rapid test device result is invalid.

Systems and methods of validation of rapid test device results with enhanced image capture

A lateral flow assay cassette comprising a swab holder is provided herein. Also provided are kits comprising the lateral flow assay cassette and methods of detecting an analyte.

Lateral flow assay cassette

Systems and methods of validation of rapid test device results

The present invention relates to compositions and methods involving diagnostic tests with multiple test antigens. The present invention involves the expanded use of test antigens as cross-reactive control antigens (CCAs). The invention advantageously provides for enhanced test results analysis by simultaneously providing both test antigen and CCA signal results. These results, in turn, allow useful sample comparison and cross-reference between samples to more accurately identify and verify the fidelity of test results obtained for multiple infective agents at once. The present invention may include compositions and methods for detecting infection by Zika virus or another flavivirus, and may distinguish between infections caused by genetically similar agents.

Immunoassay methods and compositions for detecting infection involving use of test antigens as cross-reactive control antigens

The present disclosure provides compositions and methods for detecting the presence of neutralizing antibodies in a sample. Unlike conventional assays, the methods provided herein do not require the use of live virus or virus pseudoparticles to identify neutralizing antibodies.

Neutralizing antibody immunoassays

A device for performing a multiplex lateral flow immunoassay is provided in which a liquid sample, such as a biological sample, is simultaneously tested for the presence of multiple analytes of interest. Methods that employ the device in the simultaneous detection of multiple analytes of interest within a liquid test sample are also provided.

Multiplexed lateral flow assay systems and methods for their use

The present invention provides monoclonal antibodies that are specific for the Dengue non-structural glycoprotein NS1 in monomeric and/or oligomeric (primarily dimeric) form, together with methods, including ELISA and lateral flow assays, that employ the disclosed antibodies for the early detection of Dengue virus infection. Diagnostic kits for the detection of Dengue infection are also provided, such kits including the disclosed monoclonal and/or polyclonal antibodies.

Methods and materials for the detection of dengue virus infection

A lateral flow test system together with methods for its use in the detection of one or more analytes, or components, of interest within a sample, such as a biological sample, is provided. The system comprises a liquid formulation of a gold conjugate and a lateral flow assay device that does not include a conjugate pad having conjugate dried thereon.

Growing community of inventors

Seattle, WA, United States of America

James William Needham